Form 4: Structure Therapeutics CEO Reports Share Transactions

Structure Therapeutics CEO Raymond C. Stevens reported both the acquisition of American Depositary Shares through an employee plan and the disposition of ordinary shares for tax obligations.

Summary

• Raymond C. Stevens, CEO and Director of Structure Therapeutics Inc. (GPCR), reported changes in his beneficial ownership.
• On March 3, 2026, Stevens disposed of 53,454 Ordinary Shares at a price of $20.99 per share. This disposition was due to shares being withheld by the Issuer to cover income tax obligations related to the vesting of a restricted share unit award.
• Following this transaction, Stevens directly holds 1,141,376 Ordinary Shares.
• On November 20, 2025, Stevens acquired 824 American Depositary Shares (ADSs) through the Issuer's Employee Share Purchase Plan.
• Each ADS represents three Ordinary Shares of Structure Therapeutics Inc.
• Following this acquisition, Stevens directly holds 1,824 ADSs.
• Stevens also indirectly holds 1,554,586 Ordinary Shares and 4,000 ADSs through the Stevens 2001 Revocable Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing. The tax-related sale is routine, while the ESPP acquisition indicates continued insider confidence, balancing the overall sentiment.

Positives

• Acquisition of 824 American Depositary Shares (ADSs) through the Employee Share Purchase Plan on November 20, 2025, indicating continued investment in the company by the CEO.

Negatives

• Disposition of 53,454 Ordinary Shares on March 3, 2026, to cover tax obligations related to a restricted share unit award vesting. This is a non-discretionary sale.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving tax-related dispositions, are common and generally do not reflect a change in management's long-term view of the company. The acquisition through an ESPP, however, signals continued confidence.

Related Party Transactions

• The reported transactions involve Raymond C. Stevens, CEO and Director, and the Issuer, Structure Therapeutics Inc., which are inherently related party dealings. Additionally, indirect holdings are through the Stevens 2001 Revocable Trust, co-trusteed by Raymond Stevens and Vivian Urena-Stevens.

Stakeholder Impact

• Shareholders: The transactions provide transparency into insider ownership changes. The ESPP acquisition may be seen as a positive signal of management's belief in the company. The tax-related sale is a routine event and generally not indicative of a lack of confidence.

Key Dates

Recommendation

The filing details routine insider transactions, including a tax-related disposition and an acquisition via an employee share purchase plan. These actions are common for executives and do not suggest a significant shift in the company's fundamentals or outlook. Therefore, a 'hold' recommendation is appropriate as there's no new information to warrant a change in investment thesis based solely on this filing.

Keywords

Structure Therapeutics, GPCR, Raymond C. Stevens, Insider Trading, Form 4, SEC Filing, Share Ownership, Employee Share Purchase Plan, Restricted Share Units, Tax Withholding